Novo Nordisk has two hugely successful assets in Ozempic and Wegovy. A recent trial also found semaglutide effective for treating chronic kidney disease. As these drugs accumulate more indications ...
The Danish drugmaker has high hopes that demand for its blockbuster drugs will surge in China, which is estimated to have the world’s highest number of people who are overweight or obese.
The popular weight-loss drug Wegovy has been available in Canada since early May, but anybody hoping to use it will have to shell out about $400 a month. One advocate says that lack of ...
Odds are that if you hear the word "Ozempic," you likely associate that with weight loss. It's hard not to given all the posts on social media about users losing weight thanks to the drug.
The team, led by Professor John Deanfield, conducted a five-year study to determine whether Wegovy, Ozempic and Rybelsus, could also reduce the risk of heart attacks, strokes or heart failure in ...
The new generation of weight-loss drugs were initially developed to treat diabetes and work by mimicking a hormone that regulates insulin levels and appetite. When celebrities started shedding ...
We include products we think are useful for our readers. If you buy through links on this page, we may earn a small commission. Here’s our process. Ozempic is a glucagon-like peptide (GLP-1 ...
Public interest in weight loss drugs like Wegovy and Ozempic is surging, but national data on dispensing patterns in the United States is surprisingly scarce. Now, a national study from Michigan ...
Appetite suppressing drugs are becoming a hot topic of conversation, with doctors now suggesting they could have important clinical benefits not just limited to weight loss. A new five-year study ...
Ozempic and Wegovy (semaglutide) are medications that can help lower your blood sugar, especially if you live with conditions such as diabetes or hyperglycemia (high blood sugar). These ...
Have a question for Alyssa Northrop or our other editors? Ask here for a chance to be featured in a story. Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see ...